ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
This Quarter Return
+5.12%
1 Year Return
+4.95%
3 Year Return
+16.8%
5 Year Return
+58.39%
10 Year Return
–
AUM
$77.6M
AUM Growth
+$77.6M
(-60%)
Cap. Flow
-$119M
Cap. Flow
% of AUM
-153.06%
Top 10 Holdings %
Top 10 Hldgs %
64.82%
Holding
61
New
11
Increased
2
Reduced
17
Closed
30
Top Buys
| 1 |
Agilent Technologies
A
|
$5.5M |
| 2 |
IQVIA
IQV
|
$4.31M |
| 3 |
Boston Scientific
BSX
|
$3.3M |
| 4 |
Cardinal Health
CAH
|
$3M |
| 5 |
Medtronic
MDT
|
$2.39M |
Top Sells
| 1 |
BioMarin Pharmaceuticals
BMRN
|
$18.4M |
| 2 |
Becton Dickinson
BDX
|
$16.8M |
| 3 |
Elevance Health
ELV
|
$14.1M |
| 4 |
Sabra Healthcare REIT
SBRA
|
$13.4M |
| 5 |
Teva Pharmaceuticals
TEVA
|
$6.75M |
Sector Composition
| 1 | Healthcare | 97.47% |
| 2 | Real Estate | 2.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Labcorp
LH
$23.1B
| $7.86M | 6.86% | 32,569 -12,671 | -28% | -$3.06M |
|
2
Cigna
CI
$80.3B
| $7.24M | 6.32% | 25,816 -1,983 | -7% | -$556K |
|
3
Merck
MRK
$210B
| $5.69M | 4.97% | 49,332 -241 | -0.5% | -$27.8K |
|
|
4
Agilent Technologies
A
$35.7B
| $5.5M | 4.8% | +45,762 | New | +$5.5M |
|
5
Tenet Healthcare
THC
$16.3B
| $4.72M | 4.12% | 58,036 -1,867 | -3% | -$152K |
|
6
AstraZeneca
AZN
$248B
| $4.35M | 3.8% | 60,808 -36,449 | -37% | -$2.61M |
|
|
7
IQVIA
IQV
$32.4B
| $4.31M | 3.76% | +19,169 | New | +$4.31M |
|
|
8
BioMarin Pharmaceuticals
BMRN
$11.2B
| $3.78M | 3.3% | 43,602 -212,014 | -83% | -$18.4M |
|
|
9
Becton Dickinson
BDX
$55.3B
| $3.53M | 3.08% | 13,360 -63,490 | -83% | -$16.8M |
|
|
10
Boston Scientific
BSX
$156B
| $3.3M | 2.88% | +60,991 | New | +$3.3M |
|
|
11
Cardinal Health
CAH
$35.5B
| $3M | 2.62% | +31,696 | New | +$3M |
|
12
Qiagen
QGEN
$10.1B
| $2.82M | 2.47% | 62,708 -116,186 | -65% | -$5.23M |
|
|
13
Elevance Health
ELV
$71.8B
| $2.5M | 2.19% | 5,636 -31,690 | -85% | -$14.1M |
|
|
14
Medtronic
MDT
$119B
| $2.39M | 2.09% | +27,181 | New | +$2.39M |
|
15
Encompass Health
EHC
$12.3B
| $2.21M | 1.93% | 32,710 +6,239 | +24% | +$422K |
|
16
Ventas
VTR
$30.9B
| $1.97M | 1.72% | +41,575 | New | +$1.97M |
|
17
Ocular Therapeutix
OCUL
$2.12B
| $1.9M | 1.66% | 368,438 -144,306 | -28% | -$745K |
|
18
Insmed
INSM
$28.8B
| $1.68M | 1.46% | 79,471 -150,535 | -65% | -$3.18M |
|
19
Zoetis
ZTS
$69.3B
| $1.32M | 1.15% | 7,643 -771 | -9% | -$133K |
|
20
Bruker
BRKR
$5.16B
| $1.13M | 0.98% | +15,246 | New | +$1.13M |
|
21
argenx
ARGX
$43.6B
| $1,000K | 0.87% | 2,565 -3,572 | -58% | -$1.39M |
|
|
BLUE
22
DELISTED
bluebird bio
BLUE
| $926K | 0.81% | 281,441 -243,618 | -46% | -$802K |
|
23
Cartesian Therapeutics
RNAC
$261M
| $768K | 0.67% | 686,143 -1,480,185 | -68% | -$1.66M |
|
|
ADAP
24
Adaptimmune Therapeutics
ADAP
$15.6M
| $759K | 0.66% | 821,038 -839,797 | -51% | -$777K |
|
25
Acadia Healthcare
ACHC
$2.12B
| $729K | 0.64% | +9,153 | New | +$729K |
|